Surface Oncology, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic.
Latest period: Q2 2023.
-
Location
-
Cambridge, MA
-
Fiscal year end
-
31 December
-
Latest financial report
-
02 Aug 2023
Quick Takeaways
- Surface Oncology, Inc. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q2 2023.
- Headline metric: Return On Equity -106%.
What Changed
- Return On Equity YoY change: <span class="text-green-600">+130%</span>.
- Most recent SEC facts end date: 31 Jul 2023.
Why This Matters
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Every metric card links to a deeper SEC-backed history page for verification.
Official SEC Source
Based on latest 10-Q/10-K
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original Filing
Latest SEC snapshot (2023-07-31) highlights Return On Equity -105.8%, Return On Assets -71.2%, and Current Ratio 3.6x.
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
21.9/100
Weak
Confidence medium
Return On Equity
-106%
Metric score 0.0/100
Return On Assets
-71%
Metric score 0.0/100
Financial Health
- Current Ratio
- 3.6x
- Debt to Equity
- 0.64x
Watchpoints
Return On Equity, Return On Assets, and Revenues YoY
Key metrics snapshot
Return On Equity
-106%
YoY: +130%
Industry median:
-47%
(n=218)
View history
Return On Assets
-71%
YoY: +126%
Industry median:
-44%
(n=217)
View history
Current Ratio
3.6x
YoY: -56%
Industry median:
3.67x
(n=218)
View history
Debt-to-equity
0.64x
YoY: +25%
Industry median:
0.31x
(n=169)
View history
Revenues YoY
-100%
YoY:
Industry median:
11%
(n=96)
View history
NetIncomeLoss YoY
-47%
YoY:
Industry median:
-12%
(n=211)
View history
Profitability
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Return On Equity
|
-106%
|
+130%
|
-47%
(n=218)
|
Q2 2023
|
Q2 2023
|
%
|
|
Return On Assets
|
-71%
|
+126%
|
-44%
(n=217)
|
Q2 2023
|
Q2 2023
|
%
|
Financial Health
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Current Ratio
|
3.6x
|
-56%
|
3.67x
(n=218)
|
Q2 2023
|
Q2 2023
|
x
|
|
Debt-to-equity
|
0.64x
|
+25%
|
0.31x
(n=169)
|
Q2 2023
|
Q2 2023
|
x
|
Growth
| Metric |
Latest value |
YoY change |
Industry median |
Calendar period |
Fiscal period |
Unit |
|
Revenues YoY
|
-100%
|
|
11%
(n=96)
|
Q2 2023
|
|
%
|
|
NetIncomeLoss YoY
|
-47%
|
|
-12%
(n=211)
|
Q2 2023
|
Q2 2023
|
%
|
Share Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Entity Common Stock, Shares Outstanding
|
60,824,474
|
+4.8%
|
Q2 2023
|
Q2 2023
|
shares
|
|
Common Stock, Shares, Outstanding
|
60,730,274
|
+9.7%
|
Q2 2023
|
Q2 2023
|
shares
|
|
Common Stock, Value, Issued
|
$6,000
|
0%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Weighted Average Number of Shares Outstanding, Basic
|
60,717,899
|
+11%
|
Q2 2023
|
Q2 2023
|
shares
|
|
Weighted Average Number of Shares Outstanding, Diluted
|
60,717,899
|
+11%
|
Q2 2023
|
Q2 2023
|
shares
|
Additional Metrics
| Metric |
Latest value |
YoY change |
Calendar period |
Fiscal period |
Unit |
|
Revenue from Contract with Customer, Excluding Assessed Tax
|
$0
|
-100%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Research and Development Expense
|
$59,789,000
|
-8.3%
|
Q2 2023
|
Q2 2023
|
USD
|
|
General and Administrative Expense
|
$26,362,000
|
+1.3%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Operating Income (Loss)
|
$89,385,000
|
-47%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Income Tax Expense (Benefit)
|
$0
|
|
Q2 2023
|
Q2 2023
|
USD
|
|
Earnings Per Share, Basic
|
-2
|
-24%
|
Q2 2023
|
Q2 2023
|
USD/shares
|
|
Earnings Per Share, Diluted
|
-2
|
-24%
|
Q2 2023
|
Q2 2023
|
USD/shares
|
|
Cash and Cash Equivalents, at Carrying Value
|
$14,842,000
|
-80%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Assets, Current
|
$60,588,000
|
-62%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Property, Plant and Equipment, Net
|
$2,499,000
|
-52%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Operating Lease, Right-of-Use Asset
|
$2,919,000
|
-89%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Other Assets, Noncurrent
|
$0
|
-100%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Assets
|
$66,006,000
|
-66%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Accounts Payable, Current
|
$609,000
|
+25%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Liabilities, Current
|
$16,828,000
|
-15%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Operating Lease, Liability, Noncurrent
|
$0
|
-100%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Liabilities
|
$16,828,000
|
-75%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Accumulated Other Comprehensive Income (Loss), Net of Tax
|
$221,000
|
+81%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Retained Earnings (Accumulated Deficit)
|
$252,262,000
|
-58%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Stockholders' Equity Attributable to Parent
|
$49,178,000
|
-61%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Liabilities and Equity
|
$66,006,000
|
-66%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Common Stock, Shares Authorized
|
150,000,000
|
0%
|
Q2 2023
|
Q2 2023
|
shares
|
|
Common Stock, Shares, Issued
|
60,730,274
|
+9.7%
|
Q2 2023
|
Q2 2023
|
shares
|
|
Common Stock, Par or Stated Value Per Share
|
0
|
0%
|
Q2 2023
|
Q2 2023
|
USD/shares
|
|
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
|
$91,556,000
|
-43%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Operating Lease, Liability, Current
|
$9,488,000
|
+66%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Preferred Stock, Shares Issued
|
0
|
|
Q2 2023
|
Q2 2023
|
shares
|
|
Preferred Stock, Shares Authorized
|
5,000,000
|
0%
|
Q2 2023
|
Q2 2023
|
shares
|
|
Preferred Stock, Shares Outstanding
|
0
|
|
Q2 2023
|
Q2 2023
|
shares
|
|
Share-based Payment Arrangement, Expense
|
$6,117,000
|
-22%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Interest Expense
|
$5,771,000
|
+129%
|
Q2 2023
|
Q2 2023
|
USD
|
|
Preferred Stock, Par or Stated Value Per Share
|
0
|
0%
|
Q2 2023
|
Q2 2023
|
USD/shares
|
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric |
Weight |
V1 threshold |
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Explore related SEC datasets